Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy

Vinaya Simha

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Lipodystrophy is a group of acquired and inherited disorders characterized by selective loss of adipose tissue. Despite wide genotypic and phenotypic variety, many patients with lipodystrophy have similar metabolic complications including insulin resistance, diabetes mellitus, hypertriglyceridemia and hepatic steatosis. Often, these metabolic abnormalities are severe and difficult to treat with conventional glucose and lipid-lowering therapies. Lack of adipose tissue also results in marked hypoleptinemia, and there has recently been much interest in using leptin-replacement therapy to treat the metabolic complications of lipodystrophy. Administration of metreleptin, the human recombinant leptin analogue, has been shown in prospective, open-label studies to improve glucose control, dyslipidemia and steatohepatitis. This article summarizes the current evidence for the safety and efficacy of leptin-replacement therapy in patients with lipodystrophy.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalExpert Review of Endocrinology and Metabolism
Issue number3
StatePublished - May 2014


  • Diabetes mellitus
  • Hypertriglyceridemia
  • Insulin resistance
  • Leptin therapy
  • Lipodystrophy
  • Metreleptin
  • Steatohepatitis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy'. Together they form a unique fingerprint.

Cite this